Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3918221 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRM2CHRM5CHRM3 | |
| SCHEMBL4911791 | 0.91 | CHRNB2 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL4920115 | 0.91 | CHRNB2 (0.39) | CHRNB2CHRNA4 | |
| SCHEMBL3919389 | 0.85 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRM2CHRM5CHRM3 | |
| SCHEMBL3922338 | 0.85 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRM2CHRM5CHRM3 | |
| SCHEMBL3852338 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRM2CHRM5CHRM3 | |
| SCHEMBL3930353 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRM2CHRM5CHRM3 | |
| SCHEMBL3852340 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRM2CHRM5CHRM3 | |
| SCHEMBL3930356 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRM2CHRM5CHRM3 | |
| SCHEMBL21065109 | 0.83 | HCRTR2 (0.47) | CHRNB2CHRNA4CHRM2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869032-B8 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | EP | disclosed |
| EP-1869032-B1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | ASTRAZENECA AB (SE) | 2008-07-10 | — | — | US | disclosed |
| EP-1869032-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106307-A1 | PYRIMIDINE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167297-A1 | Pyrimidine Derivatives for Use as Anticancer Agents | IGF1R, TYMP, IGFBP1 | CHRNB2 4819/4885CHRNA4 4816/4885CHRM2 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.